Aethlon Medical

Aethlon Medical, Inc. is a medical technology company which focuses on developing products to diagnose and treat life and organ threatening diseases. It develops Aethlon Hemopurifier, which is a clinical-stage immunotherapeutic device designed to combat cancer and life-threatening viral infections. The firm operates through the following segments: Aethlon and ESI. The Aethlon segment is involved in therapeutic business activities. The ESI segment consists of diagnostic business activities. The company was founded by James A. Joyce in 1991 and is headquartered in San Diego, CA.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Aethlon Medical Advances Hemopurifier, Eyes Clinical Trials

Aethlon Medical is poised for pivotal clinical trials in Australia, focusing on its Hemopurifier technology's application in cancer treatment. Financially, the company has maintained a stable cash flow, managing a modest increase in expenses. The upcoming trials and potential expansion into the organ transplant sector highlight promising growth areas.

Aethlon Medical reports financial progress and global trial expansions

Aethlon Medical's Q1 2025 earnings call highlighted financial improvements, progress in Hemopurifier research, and global clinical trial expansions.
While challenges like expense projections and trial paperwork exist, opportunities in therapy enhancement and market expansion are promising for Aethlon.
The company's commitment to innovation, financial efficiency, and stakeholder communication bodes well for its future growth and success.
Investors can find confidence in Aethlon's strategic focus on advancing therapies and expanding its global reach in the oncology space.

Aethlon Medical reports strong Q2 performance amidst oncology trial progress

Aethlon Medical's Q2 2025 performance showcased financial stability, progress in oncology trials, and strategic cost reductions.
While challenges like trial complexities and data management exist, the company's strengths in innovation and transparency offer growth opportunities.
Navigating operational challenges and leveraging trial successes can drive Aethlon's long-term success in the healthcare industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Approval eliminates the requirement for previous dialysis treatment, potentially enabling accelerated enrollment in the ongoing clinical study SAN DIEGO , July 11, 2022 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to diagnose and treat cancer and life threatening infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved an amendment to the protocol of its ongoing clinical trial investigating the Aethlon Hemopurifier® for patients with severe COVID-19. The newly approved protocol amendment eliminates the inclusion criteria that patients must have a dialysis catheter in place and have tolerated dialysis at the time of screening.

Aethlon Medical Announces U.S. FDA Approval of Hemopurifier COVID-19 Study Protocol Amendment

Aethlon Medical, Inc. (NASDAQ:AEMD ) Q4 2022 Results Conference Call June 28, 2022 4:30 PM ET Company Participants Dr. Chuck Fisher - CEO Jim Frakes - CFO Dr. Steven LaRosa - Chief Medical Officer Conference Call Participants Marla Marin - Zacks Vernon Bernardino - H.C. Wainwright Anthony Vendetti - Maxim Group Operator Good afternoon, and welcome to the Aethlon Medical Fourth Quarter Fiscal 2022 Earnings and Corporate Update Conference Call.

Aethlon Medical, Inc. (AEMD) CEO Dr. Chuck Fisher on Q4 2022 Results - Earnings Call Transcript

SAN DIEGO , June 21, 2022 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical technology to treat cancer and life-threatening infectious disease, today announced that it will issue financial results for its fiscal year ended March 31, 2022, at 4:15 p.m. EST on Tuesday, June 28, 2022.

Aethlon Medical to Release Fiscal Year End Financial Results and Host Conference Call on June 28, 2022

Chimerix

Geovax Labs

Monkeypox penny stocks to watch right now The post Top Penny Stocks To Watch As Monkeypox Cases Rise appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Top Penny Stocks To Watch As Monkeypox Cases Rise

Tonix Pharmaceuticals Hld

Monkeypox stocks to watch today. The post Penny Stocks To Buy Now?

Penny Stocks To Buy Now? Hot Monkeypox Stocks To Watch Today

SAN DIEGO, May 17, 2022 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical technology company focused on developing products to diagnose and treat life and organ threatening diseases, today announced that it will be presenting at the H.C. Wainwright Global Investment Conference.

Aethlon Medical to Present at the H.C. Wainwright Global Investment Conference

Viral capture efficiency ranged from 53% to 89% for the seven COVID-19 variants tested SAN DIEGO, May 2, 2022 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical technology company focused on developing products to diagnose and treat life and organ threatening diseases, today announced the publication of a pre-print manuscript featuring data that demonstrated Aethlon's proprietary GNA affinity resin was able to bind seven clinically relevant SARS-CoV-2 variants in vitro, including the Delta and Omicron variants. Viral capture efficiency with the GNA affinity resin ranged from 53% to 89% for all variants tested.

Aethlon Medical Publishes In Vitro Studies Demonstrating Hemopurifier Resin Binding of Seven Clinically Relevant COVID-19 Variants

SAN DIEGO, March 28, 2022 /PRNewswire/ -- Aethlon Medical, Inc. ("Aethlon") (Nasdaq: AEMD), a medical technology company focused on developing products to diagnose and treat life and organ threatening diseases, today announced the appointment of Angela Rossetti to the Aethlon Board of Directors, effective April 1, 2022. Ms. Rossetti replaces Sabrina Martucci Johnson, who has served on the Aethlon Board of Directors since 2018 and is stepping down on April 1, 2022 to focus on her other roles.

Aethlon Medical, Inc. Appoints Angela Rossetti to Board of Directors

Aethlon Medical's (AEMD) CEO Chuck Fisher on Q3 2022 Results - Earnings Call Transcript

SAN DIEGO, Jan. 31, 2022 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical technology to treat cancer and life-threatening infectious disease, today announced that it will issue financial results for its third quarter fiscal year 2022, ended December 31, 2021, at 4:15 p.m. EST on Monday, February 14, 2022.

Aethlon Medical to Release Third Quarter Financial Results and Host Conference Call on February 14, 2022

TAMPA, Fla.--(BUSINESS WIRE)---- $AEMD #505B2--Alzamend Neuro Announces Positive Topline Data from Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer's

Alzamend Neuro Announces Positive Topline Data from Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer's

Aethlon Medical, Inc. (AEMD) CEO Charles Fisher on Q2 2022 Results - Earnings Call Transcript

SAN DIEGO, Nov. 2, 2021 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical technology to treat cancer and life-threatening infectious disease, today announced that it will issue financial results for its second quarter fiscal year 2022, ended September 30, 2021, at 4:15 p.m. EST on Tuesday, November 9, 2021.

Aethlon Medical to Release Second Quarter Financial Results and Host Conference Call on November 9, 2021

SAN DIEGO, Oct. 12, 2021 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical technology to treat cancer and life-threatening infectious disease, today announced the publication of a manuscript in the peer-reviewed journal Frontiers in Medicine describing two cases of critically ill COVID-19 patients treated with the Hemopurifier®, Aethlon's therapeutic blood filtration system. The publication, titled "Removal of COVID-19 spike protein, whole virus, exosomes and exosomal microRNAs by the Hemopurifier® lectin-affinity cartridge in critically Ill patients with COVID-19 infection," is available here: https://www.frontiersin.org/articles/10.3389/fmed.2021.744141/full The publication documents two critically ill COVID-19 patients receiving a combined total of nine, six-hour Hemopurifier® treatment sessions.

Aethlon Medical Announces Peer-Reviewed Publication of Two Case Studies of Critically Ill COVID-19 Patients Treated with the Hemopurifier®

SAN DIEGO, Sept. 30,  2021 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical technology to treat cancer and life-threatening infectious disease, today announced that it has entered into an agreement with PPD, Inc. (Nasdaq: PPD), a leading global contract research organization (CRO), for PPD to oversee the company's clinical studies investigating the Hemopurifier, Aethlon's therapeutic blood filtration system, for infectious disease indications.

Aethlon Medical Announces Contracting with PPD to Advance Hemopurifier Clinical Programs

Aethlon Medical (AEMD) stock is rising higher on Wednesday due to heavy trading despite a lack of news from the company. The post 8 Things to Know About Aethlon Medical as Investors Send AEMD Stock Soaring Today appeared first on InvestorPlace.

8 Things to Know About Aethlon Medical as Investors Send AEMD Stock Soaring Today

SAN DIEGO, Sept. 7, 2021 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical technology company focused on developing products to diagnose and treat life and organ threatening diseases, today announced that it will be presenting at the H.C.

Aethlon Medical to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Aethlon Medical, Inc. (AEMD) CEO Chuck Fisher on Q1 2021 Results - Earnings Call Transcript

SAN DIEGO, July 29, 2021 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical device technology company focused on unmet needs in global health, today announced that it will issue financial results for its first quarter fiscal year 2022, ended June 30, 2020, at 4:15 p.m. EST on Monday, August 9, 2021.

Aethlon Medical to Release First Quarter Financial Results and Host Conference Call on August 9, 2021

Allied Healthcare Products

Mer Telemanagement Solutions

Novavax

Oragenics

Stocks begin week with the market selling off; why? The post This Is Why Stocks Are Down Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

This Is Why Stocks Are Down Today

SAN DIEGO, June 21, 2021 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical device technology company focused on unmet needs in global health, today announced that it will issue financial results for its fourth quarter fiscal year 2021, ended March 31, 2021, at 4:15 p.m. ET on Thursday, June 24, 2021.

Aethlon Medical to Release Fourth Quarter Financial Results and Host Conference Call on June 24, 2021

After surging 400% yesterday, Aethlon Medical, Inc. (NASDAQ: AEMD) shares are trading lower after the company announced a 1.38-million share registered direct offering priced at $9 per share. The gross proceeds to Aethlon, before deducting placement agent fees and other offering expenses, are expected to be approximately $12.425 million.

Why Aethlon Medical's Stock Is Plunging Today

SAN DIEGO, June 10, 2021 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq:AEMD), a medical device technology company focused on unmet needs in global health, today announced that it has entered into a definitive agreement with a single institutional investor for the purchase in a registered direct offering of 1,380,555 shares of its common stock, at a purchase price per share of $9.00, priced at-the-market under Nasdaq rules.  The closing of the offering is expected to occur on or about June 14, 2021, subject to the satisfaction of customary closing conditions.

Aethlon Medical Announces $12.425 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

The stock price of Aethlon Medical, Inc. (NASDAQ: AEMD) increased 388.24% yesterday. This is why it happened.

AEMD Stock Price: 388.24% Increase Explanation

Antelope Enterprise Holdings

American Software

Atomera

Checkpoint Therapeutics

Clean Energy Fuels

CynergisTek

Impac Mortgage Holdings

Pubmatic

SPI Energy

The stock prices of AEMD, CTEK, AEHL, AMSWA, CKPT, CLNE, SPI, ATOM, PUBM, and IMH have noticeably gained today. The post AEMD, CTEK, AEHL, AMSWA, CKPT, CLNE, SPI, ATOM, PUBM, IMH Stock Prices Gain Intraday appeared first on Pulse 2.0.

News for Aethlon Medical Stock (AEMD)